These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 22258344)
1. Unicentric Castleman disease relapsed after rituximab-CHOP chemotherapy or radiation therapy in an adolescent. Baek HJ; Kook H; Han DK; Shin MG; Kim HS; Hwang TJ J Pediatr Hematol Oncol; 2012 Jul; 34(5):e206-8. PubMed ID: 22258344 [TBL] [Abstract][Full Text] [Related]
2. Surgical resection combined with CHOP chemotherapy plus rituximab for a patient with advanced mesenteric diffuse large B cell lymphoma. Yamaguchi T; Takahashi H; Kagawa R; Takeda R; Sakata S; Nishizaki D; Takamatsu T; Iwasa Y Hepatogastroenterology; 2008; 55(84):891-4. PubMed ID: 18705290 [TBL] [Abstract][Full Text] [Related]
3. Castleman disease and adenocarcinoma. Megalakaki A; Evmorfiadis I; Stamouli M; Zakopoulou N; Iacovidou I J BUON; 2011; 16(4):781-2. PubMed ID: 22331742 [No Abstract] [Full Text] [Related]
4. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A Oncology; 2006; 70(6):411-7. PubMed ID: 17220639 [TBL] [Abstract][Full Text] [Related]
5. Complete remission in 4 patients with human herpesvirus 8-associated multicentric Castleman disease using rituximab and liposomal doxorubicin, a novel chemotherapy combination. Peker D; Martinez AE; Schwartz MA; Cusnir M Clin Adv Hematol Oncol; 2012 Mar; 10(3):204-6. PubMed ID: 22402431 [No Abstract] [Full Text] [Related]
6. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473 [TBL] [Abstract][Full Text] [Related]
7. Surgical outcome of superficial and deep Castleman disease. Chen CH; Liu HC; Tung KY; Lee JJ; Liu CL; Liu TP ANZ J Surg; 2007 May; 77(5):339-43. PubMed ID: 17497971 [TBL] [Abstract][Full Text] [Related]
8. Rituximab CHOP for successful management of diffuse large B-cell lymphoma of the ovary. Ahbeddou N; Fetohi M; Khanoussi BE; Errihani H Arch Gynecol Obstet; 2011 May; 283(5):1173-4. PubMed ID: 20957380 [No Abstract] [Full Text] [Related]
9. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy. Johnston A; Salles G; Espinouse D; Felman P; André P; Berger F; Coiffier B Clin Lymphoma Myeloma; 2008 Dec; 8(6):356-8. PubMed ID: 19064401 [TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562 [TBL] [Abstract][Full Text] [Related]
12. IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report. Galeotti C; Tran TA; Franchi-Abella S; Fabre M; Pariente D; Koné-Paut I J Pediatr Hematol Oncol; 2008 Dec; 30(12):920-4. PubMed ID: 19131781 [TBL] [Abstract][Full Text] [Related]
14. Rituximab tolerability when given before or after CHOP. Hannawa IS; Bestul DJ J Oncol Pharm Pract; 2011 Dec; 17(4):381-6. PubMed ID: 21109616 [TBL] [Abstract][Full Text] [Related]
15. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255 [TBL] [Abstract][Full Text] [Related]
16. Primary lymphoma of the uterus and cervix: two case reports and review of the literature. Upanal N; Enjeti A Aust N Z J Obstet Gynaecol; 2011 Dec; 51(6):559-62. PubMed ID: 21923699 [TBL] [Abstract][Full Text] [Related]
17. Cervical unicentric Castleman disease presenting as a neck mass: case report and review of the literature. Liang J; Newman JG; Frank DM; Chalian AA Ear Nose Throat J; 2009 May; 88(5):E8. PubMed ID: 19444782 [TBL] [Abstract][Full Text] [Related]
18. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Kurokawa T; Hase M; Tokuman N; Yoshida T Hematol Oncol; 2011 Mar; 29(1):5-9. PubMed ID: 20552573 [TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. Smith SD; Bolwell BJ; Rybicki LA; Kang T; Dean R; Advani A; Thakkar S; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW Bone Marrow Transplant; 2011 Feb; 46(2):262-6. PubMed ID: 20479706 [TBL] [Abstract][Full Text] [Related]
20. [Intravascular large B-cell lymphoma: an important cause of fever of unknown origin]. Masaki Y; Miki M; Sakai T; Sawaki T; Fukushima T; Umehara H Brain Nerve; 2011 May; 63(5):435-41. PubMed ID: 21515922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]